证券代码：301293 证券简称：三博脑科 公告编号：2025-026 | | | | | | | 占剔除公司回 | | --- | --- | --- | --- | --- | --- | --- | | 股东 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 占公司目前 | 购专用账户股 | | 名称 | | | （元） | （股） | 总股本比例 | 份数量后总股 | | | | | | | | 本的比例 | | TBP | 集中竞价 | 2025.4.18-2025.7.11 | 45.21 | 1,124,600 | 0.546% | 0.554% | 1、股东减持股份情况 三博脑科医院管理集团股份有限公司 关于持股 5%以上股东减持股份计划期间届满暨实施情况的公告 公司股东 TBP 3Doctors (HK) Limited 保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日披露了《关于持股 5%以上 ...

Core Insights - Vand Investment recently conducted research on Sanbo Brain Science, highlighting the company's success in the world's first interventional brain-computer interface trial for restoring motor function in patients [1] - The company is expanding its network with new hospital branches in Beijing, Kunming, Xi'an, and Hunan, aiming to enhance medical service capabilities [1] - Sanbo Brain Science is focusing on a nationwide chain operation model and plans to establish over ten group-controlled hospitals while strengthening technological innovation and research成果转化 [1] Company Developments - The chairman's personal reasons do not affect the company's operations [1] - The company has a well-established talent training system, with medical personnel in local hospitals being recruited locally and trained in Beijing [1] - The proportion of medical insurance income varies by region, with Beijing's Sanbo Brain Science having about 30% of its income from insurance, while most out-of-town hospitals exceed this figure [1] Financial Performance - New hospital branches have different ramp-up periods, with Fujian Sanbo typically reaching breakeven in about three years, while Henan Sanbo is expected to improve its operational status in the future [1] - The company has repurchased shares for employee stock ownership plans and will implement this at an appropriate time [1] Market Context - The aging population is leading to an increase in degenerative diseases, particularly in the cardiovascular and neurological sectors, which will influence the company's future business growth [1] - The patient demographic spans a wide age range, from newborns to nonagenarians, with patient sources including reputation, technical training, and local expert collaborations [1] - The company actively fulfills social responsibilities through free clinics, discipline construction, and establishing brain health communities [1] Regulatory Environment - Short-term impacts from medical insurance policies are minimal, but long-term contributions to revenue are expected [1] - The DRG (Diagnosis-Related Group) single disease payment system has varying impacts on different hospital branches [1] - The application of brain-computer interfaces is still in the preliminary experimental verification stage, with more mature applications in neuroregulation for treating elderly Parkinson's disease and epilepsy [1]

Summary of the Conference Call for Sanbo Brain Science Company Overview - **Company**: Sanbo Brain Science - **Industry**: Healthcare, specifically focusing on brain-machine interface technology and neurosurgery Key Points and Arguments Financial Performance - **Revenue Stability**: Revenue for the first half of the year remained flat compared to the previous year, with growth observed in Beijing, Henan, and Fujian regions, while Kunming faced challenges due to relocation [2][3] - **Profit Growth**: Expected single-digit profit growth attributed to supply chain optimization and contributions from newly acquired hospitals, with the Chengdu hospital maintaining positive profitability [2][3] Technological Advancements - **Clinical Trials**: Successful completion of an interventional brain-machine interface trial in Fujian, with plans for another trial in Beijing [2][5] - **Research Collaboration**: Joint research projects with universities focusing on early-stage technology research for epilepsy and Parkinson's disease, with minimal fees charged [10][11] New Hospital Developments - **New Facilities**: Progress on new hospital locations, with the Beijing facility expected to relocate in Q1 2025, and the Kunming facility now operational after relocation [2][6] Industry Challenges - **Impact of DRG Payment System**: The implementation of the DRG (Diagnosis-Related Group) payment system has led to a decrease in inpatient costs by approximately 10%, necessitating an increase in patient volume to offset revenue losses [4][16] - **Market Dynamics**: A shift in patient preferences towards pharmacies and clinics due to perceived cost-effectiveness, impacting hospital visit numbers [16] Future Growth Strategies - **M&A Fund**: Establishment of a 300 million yuan merger and acquisition fund aimed at acquiring and incubating hospitals, with contributions from the company, local governments, and large pharmaceutical companies [4][13] - **Expansion Plans**: Plans to expand into the Yangtze River Delta and Pearl River Delta regions through acquisitions, with a focus on enhancing operational efficiency and service quality [16][17] Clinical Application of Brain-Machine Interface Technology - **Current Status**: The technology is in the early clinical validation stage, primarily focused on experimental verification, with applications in neuro-regulation for conditions like Parkinson's disease and epilepsy [7][9] Talent Acquisition and Incentives - **Attracting Talent**: The hospital offers flexible mechanisms and equity incentives to attract core experts, providing significant career advancement opportunities compared to traditional public hospitals [18][19] Collaboration with Universities - **Resource Utilization**: Collaboration with universities to leverage resources for research and teaching, ensuring high-quality support for clinical and academic endeavors [20] Financial Management of Acquisitions - **Risk Management**: Contracts for new acquisitions include provisions for potential risks such as Medicare deductions and legal disputes, ensuring effective management of hidden liabilities [26] Additional Important Information - **AI Integration**: Current clinical and management operations have not fully integrated AI models, with a cautious approach towards evaluating the effectiveness of such technologies [22][23] - **Patient Volume Trends**: Observations indicate a decline in hospital visits, with a notable increase in business for clinics and pharmacies [16][24] This summary encapsulates the key insights from the conference call, highlighting the company's performance, strategic initiatives, and industry challenges.

三博脑科医院管理集团股份有限公司 投资者关系活动记录表 编号：2025-002 | | ☑特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华泰联合：刘恋、朱珂莹、郭敏、董光启、温北怡、马影 | | | 林锐基金：姬永锋、饶伟、邱仁裕、丁威 | | | 首都科技发展集团：李琦萱、孟剑飞 | | | 本分投资：张梦芸、吴林生 | | | 焦桐基金：李建东釜泽投资：罗荆 | | | 烜鼎私募：纵蕾影汇隆科技：姚晓兵 | | | 辰兴高科：刘洋寒武纪（北京）投资：程浩楠 | | | 国中长城：刘志强天风证券：王新 | | 人员姓名 | 格拉汉维尔：王艳紫时基金：丁帅 | | | 粤开证券：吴争辉和信证券：王剑华、钱立峰 | | | AEKE家办：王锡波 国新证券：李奕 | | | 东北证券：张静茹凡德投资：高原源 | | | 远景资本：应丽 | | | 国金证券：韩旖旎、甘坛焕 | | 时间 | 2025年7月8日 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sanbo Brain Science, indicating a significant increase in shareholder numbers and a high PE ratio compared to industry averages [1][2] - As of July 4, Sanbo Brain Science's closing price was 50.55 yuan, with a PE ratio of 94.75 times, and a total market capitalization of 10.413 billion yuan [1] - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.26 times, positioning Sanbo Brain Science at the 39th rank within the industry [1][2] Group 2 - As of March 31, 2025, the number of shareholders for Sanbo Brain Science increased to 37,673, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The main business of Sanbo Brain Science includes clinical medical services, with key products being medical services, pharmaceuticals, and supply chain operations [1] - In the first quarter of 2025, the company reported revenue of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.3136 million yuan, reflecting a year-on-year growth of 14.56%, with a gross margin of 26.44% [1]

Core Viewpoint - The healthcare services sector experienced a decline of 1.45% with a net outflow of 1,102.31 million in funds, indicating a bearish trend in the market [1] Group 1: Sector Performance - The healthcare services sector saw a total of 2 stocks rising and 41 stocks declining [1] - The top ten decliners in the sector included Sanbo Brain Science (-4.57%), Ruizhi Medicine (-4.56%), and Innovation Medical (-4.34%) [1] Group 2: Stock Details - Sanbo Brain Science closed at 49.87 with a decline of 4.57% and a net fund outflow of 108.09 million [1] - Ruizhi Medicine closed at 10.88, down 4.56%, with a net outflow of 68.69 million [1] - Innovation Medical closed at 15.00, down 4.34%, with a net outflow of 320.40 million [1] - Other notable decliners included Maipu Medical (-3.79%), Nuotai Biological (-3.40%), and Dae Oriental (-3.21%) [1] Group 3: Gainers - The stocks that gained included *ST Biological with an increase of 3.83% and Chengda Pharmaceutical with an increase of 1.03% [1]

证券代码：301293 证券简称：三博脑科 公告编号：2025-025 一致。 三博脑科医院管理集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 账户中的回购股份 2,997,183 股不参与本次权益分派。本次权益分派将以公司总 股本 205,986,987 股剔除回购专用证券账户中已回购股份 2,997,183 股后的股本 合计派发现金红利人民币 30,042,490.99 元（含税）。2024 年度不送红股，不进 行资本公积转增股本。 折算的每 10 股现金分红（含税）=现金分红总额/总股本*10 股=30,042,490.99 元 /205,986,987 股*10 股=1.458465 元（保留到小数点后六位，最后一位直接截取， 不四舍五入）。 按公司总股本（含回购股份）折算的每股现金红利=股权登记日收盘价-0.1458465 元/股。 公司 2024 年度权益分派方案已获 2025 年 5 月 16 日召开的公司 2024 年年度 股东会审议通过，现将权益分派事宜公告如下： 一、股东会审议通过利润分配方案情况 以公司总股本 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-025 三博脑科医院管理集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、本次权益分派实施后计算除权除息价格时，按公司总股本（含回购股份） 折算的每 10 股现金分红（含税）=现金分红总额/总股本*10 股=30,042,490.99 元 /205,986,987 股*10 股=1.458465 元（保留到小数点后六位，最后一位直接截取， 不四舍五入）。 3、本次权益分派实施后，除权除息参考价格=除权除息前一交易日收盘价- 按公司总股本（含回购股份）折算的每股现金红利=股权登记日收盘价-0.1458465 元/股。 公司 2024 年度权益分派方案已获 2025 年 5 月 16 日召开的公司 2024 年年度 股东会审议通过，现将权益分派事宜公告如下： 一、股东会审议通过利润分配方案情况 1、公司于 2025 年 5 月 16 日召开的 2024 年年度股东会审议通过了《关于 2024 年度利润分配预案的议案》。 以公司总股本205,986, ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by advancements from companies like Neuralink and recent breakthroughs in China, indicating a potential commercialization of BCI technology in the near future [2][4][5]. Group 1: Neuralink Developments - Neuralink has showcased its latest research and product development, with 7 participants currently using the device for an average of 50 hours per week, peaking over 100 hours [2]. - The company plans to implant devices in the speech cortex by the end of 2025 to decode silent speech from brain signals, and aims to increase electrode channels to 3,000 by 2026 to explore restoring vision [2][3]. - By 2028, Neuralink anticipates implanting over 25,000 electrodes to address mental health issues and explore integration with AI, potentially allowing humans to control robots directly [3]. Group 2: Market Potential and Growth - The global BCI market is projected to grow from $2.62 billion in 2024 to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% [4]. - The BCI technology is recognized as one of the most disruptive technologies of the 21st century, with expectations for a surge in medical product applications over the next 5 to 10 years [4]. Group 3: Domestic Developments in China - Recent successful trials in China, including the first invasive BCI-assisted rehabilitation for a stroke patient, highlight the rapid advancement of BCI technology towards commercialization [4]. - The "Beijing Brain Institute" has developed a flexible, high-throughput, semi-invasive BCI system that has entered clinical trials, marking significant progress in the field [4]. Group 4: Industry Insights - The domestic BCI industry is benefiting from technological breakthroughs and supportive government policies, which are expected to accelerate the commercialization process [5]. - BCI products are categorized into non-invasive and invasive types, with non-invasive products leading in commercialization, while invasive products are still in clinical research stages [6]. - Despite the promising outlook, the BCI industry faces challenges related to safety, regulatory approval, and the need for foundational research [6][7].

A股脑机接口板块高开，际华集团涨停，爱朋医疗涨超7%，创新医疗、南京熊猫、三博脑科等跟涨。 ...